Lemmon CA, Zabor EC, Pennell NA. Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer. Oncologist 2022 Mar 14. pii: 6548144. doi: 10.1093.
PMID: 35285487